A second potential COVID-19 vaccine, backed by the Bill and Melinda Gates Foundation, has entered Phase 1 of clinical human testing, after being allowed by the US Food and Drug Administration. The 'INO-4800' DNA vaccine candidate, developed by Inovio Pharmaceuticals, is being tested in around 40 adults. The study's initial immune responses and safety data are expected by late summer.